Catalent (Somerset, NJ), already a leader in softgel drug composition, is bidding to acquire Accucaps, based in Strathroy, ON, pending Canadian government approval. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s, says the company.
In 2014, Accucaps opened a multimillion-dollar Specialty Products Suite at its Windsor, ON, facility, with enhanced capability to handle high-potency ingredients. Both companies offer softgels for pharma and OTC products; Catalent has an extensive portfolio of oral, topical and other formulation technologies.
Simultaneously with the Accucaps news, Catalent announced that its wholly owned subsidiary, Catalent Pharma Solutions, would be offering a private placement of $400 million in “euro-denominated senior unsecured notes due 2024,” with the proceeds to fund the acquisition of Accucaps and, repay other debts and add to its cash holdings.